BiotechTubeBiotechTube
Home/Pipeline/AT-017

AT-017

Breast Cancer

Not SpecifiedActive

Key Facts

Indication
Breast Cancer
Phase
Not Specified
Status
Active
Company
Asieris Pharmaceuticals

About Asieris Pharmaceuticals

Founded in 2010 and publicly listed in China (688176.SH), Asieris Pharmaceuticals is a global biopharma leader in genitourinary and women's health. Its strategy integrates in-house R&D with global partnerships, supported by advanced technology platforms for drug discovery. The company has achieved significant milestones, including the approval of its first-in-class therapy Cevira® in China and the submission of a Marketing Authorization Application to the European Medicines Agency.

View full company profile

Therapeutic Areas

Urologic OncologyWomen's HealthBreast and Gynecologic OncologyAutoimmune DiseasesInfectious Diseases

Other Breast Cancer Drugs

DrugCompanyPhase
Verzenio (abemaciclib)Eli LillyApproved
Pan-mutant-selective PI3Kα inhibitorNovartisAcquisition
TrodelvyRoyalty PharmaCommercial
Trastuzumab biosimilar (IBI306)Innovent BiologicsPhase 3
Ogivri (trastuzumab biosimilar)ViatrisApproved
Trastuzumab BiosimilarDr. Reddy's LaboratoriesApproved
Biosimilar TrastuzumabCiplaCommercial
Ogivri (Trastuzumab)BioconApproved
TamoxifenNatco PharmaApproved
ARV-027ArvinasPhase 1
Prognostic Genomic TestsEurobio ScientificCommercial
SelinexorKaryopharm TherapeuticsClinical Trials